Federated Hermes Inc. Has $33,000 Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Federated Hermes Inc. decreased its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 96.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,886 shares of the company's stock after selling 48,152 shares during the quarter. Federated Hermes Inc.'s holdings in Progyny were worth $33,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Signaturefd LLC lifted its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares during the last quarter. GAMMA Investing LLC raised its position in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares during the period. Caitlin John LLC lifted its holdings in Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Progyny in the fourth quarter valued at approximately $74,000. Institutional investors own 94.93% of the company's stock.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group upped their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Bank of America increased their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a report on Monday, March 31st. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Progyny presently has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Stock Up 0.8 %

Shares of Progyny stock traded up $0.17 during trading hours on Thursday, hitting $22.50. 87,215 shares of the company's stock traded hands, compared to its average volume of 1,751,170. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $33.84. The stock has a 50 day simple moving average of $21.93 and a 200-day simple moving average of $18.96. The company has a market cap of $1.93 billion, a PE ratio of 38.83, a PEG ratio of 2.39 and a beta of 1.33.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.